Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data.
Pharmacogenomics J. 2010 Aug;10(4):278-91. doi: 10.1038/tpj.2010.57.
Pharmacogenomics J. 2010.
PMID: 20676067
Free PMC article.
Microarrays in the clinic.
Tillinghast GW.
Tillinghast GW.
Nat Biotechnol. 2010 Aug;28(8):810-2. doi: 10.1038/nbt0810-810.
Nat Biotechnol. 2010.
PMID: 20697405
No abstract available.
Item in Clipboard
The microtubule targeting agent ST-401 triggers cell death in interphase and prevents the formation of polyploid giant cancer cells.
Vicente JJ, Khan K, Tillinghast G, McFaline-Figueroa JL, Sancak Y, Stella N.
Vicente JJ, et al. Among authors: tillinghast g.
J Transl Med. 2024 May 10;22(1):441. doi: 10.1186/s12967-024-05234-3.
J Transl Med. 2024.
PMID: 38730481
Free PMC article.
Item in Clipboard
Mitosis exit followed by death in interphase prevents the development of polyploid giant cancer cells.
Vicente JJ, Khan K, Tillinghast G, McFaline-Figueroa JL, Sancak Y, Stella N.
Vicente JJ, et al. Among authors: tillinghast g.
bioRxiv [Preprint]. 2023 Oct 5:2023.08.31.555795. doi: 10.1101/2023.08.31.555795.
bioRxiv. 2023.
PMID: 37693393
Free PMC article.
Updated.
Preprint.
Item in Clipboard
Free energy calculations of ALS-causing SOD1 mutants reveal common perturbations to stability and dynamics along the maturation pathway.
Wells NGM, Tillinghast GA, O'Neil AL, Smith CA.
Wells NGM, et al. Among authors: tillinghast ga.
Protein Sci. 2021 Sep;30(9):1804-1817. doi: 10.1002/pro.4132. Epub 2021 Jun 22.
Protein Sci. 2021.
PMID: 34076319
Free PMC article.
Item in Clipboard
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA.
Borson R, et al. Among authors: tillinghast g.
Clin Breast Cancer. 2012 Oct;12(5):322-30. doi: 10.1016/j.clbc.2012.07.004.
Clin Breast Cancer. 2012.
PMID: 23040000
Clinical Trial.
Item in Clipboard
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR.
Hainsworth JD, et al. Among authors: tillinghast gw.
Clin Adv Hematol Oncol. 2012 Apr;10(4):240-6.
Clin Adv Hematol Oncol. 2012.
PMID: 22706484
Clinical Trial.
Item in Clipboard
Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.
Tillinghast GW, Partee J, Albert P, Kelley JM, Burtow KH, Kelly K.
Tillinghast GW, et al.
Genes Chromosomes Cancer. 2003 Jun;37(2):121-31. doi: 10.1002/gcc.10195.
Genes Chromosomes Cancer. 2003.
PMID: 12696060
Item in Clipboard
Cite
Cite